Clinical trials cd47 nih

Author: qbex

August undefined, 2024

WebMay 3, 2024 · Specifically, research is encouraged in understanding the mechanisms of immune and/or autoimmune pathways that could be applied to improving … WebJan 17, 2024 · CD47 is a “don’t eat me” signal to phagocytes that is overexpressed on many tumor cells as a potential mechanism for immune surveillance evasion. CD47 and its interaction with signal-regulating protein alpha (SIRPα) on phagocytes is therefore a promising cancer target.

Finding a Clinical Trial National Institutes of Health (NIH)

WebHumanized CD47 antibodies are showing promise in early clinical trials, but side effects related to enhanced phagocytic clearance of circulating blood cells remain a concern. Approaches to circumvent these include antibody preloading strategies, development of antibodies that recognize tumor-specific epitopes of CD47, SIRPα antibodies, and ... WebMar 22, 2024 · Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention. They are the primary way that researchers find out if a new treatment, like a … oakham shires

CD47–SIRPα-targeted therapeutics: status and prospects - PMC

WebClinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors. The project objective is to complete two staggered Phase 1 clinical trials, beginning with a solid tumor trial at Stanford. WebObjectives: CD47 is a transmembrane receptor that inhibits phagocytosis. Over-expression of CD47 is associated with an increased risk of tumor growth and metastasis. Clinical trials based on anti-CD47 therapy in adults are underway in a variety of malignancies. CD47 has been shown to be over-expressed in conventional hepatocellular carcinoma ... WebExpert opinion: RRx-001 is the first reported small molecule downregulator of CD47 and SIRPα and lacks any notable hematologic or systemic toxicity as demonstrated in clinical trials to date. Small molecule RRx-001 could be used in combination with or in place of CD47 targeting antibodies for anti-cancer treatment. Keywords: mailing with dry ice

CD47 Institute for Stem Cell Biology and Regenerative Medicine ...

WebTargeting CD47 is in the spotlight of cancer immunotherapy. Blocking CD47 triggers the recognition and elimination of cancer cells by the innate immunity. There are three CD47 antagonists in phase I clinical trials, but their potential efficacies are highly controversial. WebApr 10, 2024 · Results: We identified 13 patients (acute myeloid leukemia, n = 8; B-acute lymphoblastic leukemia, n = 3; myelodysplastic syndrome, n = 2) aged 4 months to 27 years. A median of 3 prior lines of therapy weregiven (range 0-5). All patients received venetoclax in combination with either a hypomethylating agent or conventional chemotherapy. mailing without stampWebApr 24, 2012 · We have previously shown that the presence of TAMs in LMS is associated with poor clinical outcome and the overall effect of TAMs in LMS therefore appears to be protumorigenic. However, the use of inhibitory antibodies against CD47 offers an opportunity to turn TAMs against LMS cells by allowing the phagocytic behavior of resident … oakham shires school

"WebJun 23, 2024 · NIH investigators hope CD47 study leads to broad-spectrum infectious diseases immunotherapy. Colorized scanning electron micrograph of a cell (purple) … " - Clinical trials cd47 nih

Clinical trials cd47 nih

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

WebWith these advances in the design of CD47-SIRPα-targeting therapeutic strategies and increasing insight into the mechanism of action of this innate checkpoint, including the role of adaptive immunity, further advances in the clinical application of this … WebClinical trials are voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, …

Did you know?

WebSep 6, 2024 · To see current clinical trials that are offered through the Developmental Therapeutics Clinic, visit the list of open DTC trials. For contact information for the Clinical Research Referral Coordinators and … WebJul 13, 2024 · Early clinical trials of anti-CD47 Hu5F9-G4 alone or in combination with rituximab showed promising results in patients with non-Hodgkin’s,45 46 with a total of 50% of patients with an objective response and 36% with a complete response.45 In the phase I ASPEN-01 clinical trial, evorpacept (CD47-binding domain of SIRPα fused to an …

WebMacrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function The macrophage checkpoint is an anti-phagocytic interaction between signal regulatory protein alpha (SIRPα) on a macrophage and CD47 on all types of cells - ranging from blood cells to cancer cells. WebJun 30, 2024 · Clinical trials, also known as clinical studies, test potential treatments in human volunteers to see whether they should be approved for wider use in the general …

WebNov 11, 2024 · CD47-SIRPα interaction acts as a "don't eat me" signal and is exploited by cancer to downregulate innate and adaptive immune surveillance. There has been intense interest to develop a mechanism of blockade, and we aimed to analyze the emerging data from early clinical trials. WebIn this study, we examined the combination of CD47 blockade with anti-CD20 passive immunotherapy for canine lymphoma. The CD47/SIRPα axis is an immune checkpoint that regulates macrophage activation. In humans, CD47 is expressed on cancer cells and enables evasion from phagocytosis.

WebJan 15, 2024 · CD47 Antigen / genetics* Humans Immunotherapy / methods* Macrophages / metabolism* Magnetic Resonance Imaging / methods* Mice Nanoparticles / metabolism* Osteosarcoma / genetics* Osteosarcoma / pathology Antibodies, Monoclonal CD47 Antigen CD47 protein, human

WebApr 20, 2024 · On the basis of tolerability and receptor occupancy studies that showed 100% CD47 saturation on RBCs, 1 mg/kg was selected as the priming dose. In … mailing wizard wordWebClinical trials are conducted according to a plan, called a protocol, which describes: what the researchers hope to learn from the study. Volunteers who participate in the study … oakham school websiteWebApr 11, 2024 · A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant Tumors ... ( Other Identifier: CTEP ) UM1CA186690 ( U.S. NIH Grant/Contract ) First Posted: April 11, 2024 Key Record Dates: Last Update Posted: April 11, 2024 ... For more details on how clinical trial data is … mailing wine uspsWebApr 13, 2024 · Feature papers represent the most advanced research with significant potential for high impact in the field. ... signal, is a target for many cancer types, including breast tumors, understanding the molecular events that increase CD47 expression is a clinical need. In recent years, exosomes have become appreciated as mediators of cell … mailingwork gmbh chemnitzWebApr 11, 2024 · A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant Tumors ... ( Other Identifier: CTEP ) … mailing with excelWebNov 6, 2024 · NIH conducts clinical research trials for many diseases and conditions, including cancer, Alzheimer’s disease, allergy and infectious diseases, and neurological disorders. To search for other diseases and conditions, you can visit ClinicalTrials.gov. This is a searchable registry and results database of federally and privately supported ... mailingwork chemnitzWebFeb 15, 2024 · The signal regulatory protein α (SIRPα)/CD47 axis has emerged as an important innate immune checkpoint that enables cancer cell escape from macrophage phagocytosis. SIRPα expression is limited to macrophages, dendritic cells, and neutrophils-cells enriched in the tumor microenvironment. mailing with stamps